scispace - formally typeset
H

Heike Münzberg

Researcher at Pennington Biomedical Research Center

Publications -  70
Citations -  5402

Heike Münzberg is an academic researcher from Pennington Biomedical Research Center. The author has contributed to research in topics: Leptin & Energy homeostasis. The author has an hindex of 29, co-authored 66 publications receiving 4272 citations.

Papers
More filters
Journal ArticleDOI

Impaired branched chain amino acid metabolism alters feeding behavior and increases orexigenic neuropeptide expression in the hypothalamus.

TL;DR: The data suggest that either BCAAs do not act as physiological signals of protein status or the loss of BCAA metabolism within brain glia impairs the detection of protein balance.
Journal ArticleDOI

Eating in mice with gastric bypass surgery causes exaggerated activation of brainstem anorexia circuit.

TL;DR: The neural activation pattern and dynamics suggest a role of the brainstem anorexia pathway in the early effects of RYGB on meal size and food intake that may lead to adaptive neural and behavioral changes involved in the control of food intake and body weight at a lower level.
Journal ArticleDOI

Roux-en-Y Gastric Bypass Surgery-Induced Weight Loss and Metabolic Improvements Are Similar in TGR5-Deficient and Wildtype Mice.

TL;DR: It is concluded that bile acid signaling through TGR5 is not required for the beneficial effects of RY GB in the mouse and that RYGB and VSG may achieve their similar beneficial effects through different mechanisms.
Journal ArticleDOI

Reversible hyperphagia and obesity in rats with gastric bypass by central MC3/4R blockade.

TL;DR: To test the commonly held assumption that gastric bypass surgery lowers body weight because it limits the ability to eat large amounts of food, a large amount of food is eaten in order to test the assumption.
Journal ArticleDOI

Roux-en-Y gastric bypass surgery is effective in fibroblast growth factor-21 deficient mice

TL;DR: FGF21 signaling is not a critical single factor for the beneficial metabolic effects of RYGB, which may open up the possibility to use FGF21 as adjuvant therapy in patients with ineffective bariatric surgeries.